utilities

Archive | Government and policy

MP Daniel Zeichner visits Alzheimer’s Research UK

Kirsty MaraisClare van LyndenSusan MitchellEmily CookHelen Davies

Protecting dementia research in a post-Brexit Britain with Daniel Zeichner MP Even though it has been more than seven months since Britain voted to leave the EU, we are still in a state of uncertainty about exactly what Brexit will look like and we do not yet fully understand the impact this decision will have […]

Over-65s to be given better advice about dementia at NHS Health Checks

Kirsty MaraisClare van LyndenSusan MitchellEmily CookHelen Davies

As the UK’s leading dementia research charity, one of the biggest challenges we face is raising awareness and understanding of dementia. Too often people wrongfully believe dementia is an inevitable part of ageing and that there is nothing they can do to reduce their risk. But that’s not the case, which is why Alzheimer’s Research […]

Keeping up the momentum

Kirsty MaraisClare van LyndenSusan MitchellEmily CookHelen Davies

At Alzheimer’s Research UK we recognise that we aren’t going to defeat dementia on our own. We will need the combined and coordinated effort of a number of different stakeholders, including governments. Therefore, a key strand of activity for the charity is ensuring that dementia research has the support of the UK government. We do […]

Looking to the future

David Mowat MP

I recently attended Alzheimer’s Research UK’s event at the Conservative party conference – “Looking to the future: Innovative approaches in the fight against dementia”. I was impressed with some of the creative ways the charity is raising awareness and highlighting the power of research to defeat dementia. A look at just some of the statistics […]

Read more

New report recommends plan for Government to accelerate access to new medicines at ‘crucial time’ for dementia

Kirsty MaraisClare van LyndenSusan MitchellEmily CookHelen Davies

Today sees the publication of the final report of the Accelerated Access Review, which seeks to accelerate access to all new innovations, including drugs, diagnostics and medical technologies.  The recommendations of this review will be critical in addressing the challenges new dementia treatments are likely to face and will set the scene for access to […]

Drug discovery and the pharmaceutical industry: collaborating for progress

Kirsty MaraisClare van LyndenSusan MitchellEmily CookHelen Davies

Dementia is too big a challenge for one organisation to tackle alone. As the UK’s leading dementia research charity, we’re proud to be funding cutting-edge, innovative science, but we’re also continually working to encourage investment across the board. To develop new treatments for dementia, we need a thriving research sector, and the pharmaceutical industry is a […]

Dementia risk reduction – supporting research to develop the evidence base

Kirsty MaraisClare van LyndenSusan MitchellEmily CookHelen Davies

There is increasing recognition that a mixture of genetic, lifestyle and health factors are likely to contribute to whether someone develops dementia at a particular age. The growing evidence base has linked a number of risk factors to dementia, including smoking, lack of exercise, low education, high blood pressure, and diabetes, with some studies now […]

The Higher Education and Research Bill – what this could mean for dementia research

Kirsty MaraisClare van LyndenSusan MitchellEmily CookHelen Davies

Today the Higher Education and Research Bill, which proposes changes to the structures and funding mechanisms for teaching and research in Universities, starts the next stage of its journey towards becoming law as it reaches committee stage in Westminster. So what does the Bill propose, and why does it matter to dementia research? The Bill […]